Deltec Asset Management LLC Acquires New Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE)

Deltec Asset Management LLC bought a new position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 194,124 shares of the company’s stock, valued at approximately $514,000. Deltec Asset Management LLC owned 0.67% of Aerovate Therapeutics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in AVTE. GSA Capital Partners LLP lifted its holdings in shares of Aerovate Therapeutics by 226.8% in the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock valued at $865,000 after buying an additional 287,163 shares during the period. FMR LLC lifted its holdings in Aerovate Therapeutics by 54,095.4% in the 3rd quarter. FMR LLC now owns 82,919 shares of the company’s stock valued at $173,000 after acquiring an additional 82,766 shares during the last quarter. FNY Investment Advisers LLC bought a new position in shares of Aerovate Therapeutics during the 4th quarter valued at about $198,000. Cubist Systematic Strategies LLC acquired a new position in shares of Aerovate Therapeutics in the 2nd quarter worth approximately $53,000. Finally, State Street Corp raised its holdings in shares of Aerovate Therapeutics by 7.7% in the 3rd quarter. State Street Corp now owns 367,468 shares of the company’s stock worth $768,000 after purchasing an additional 26,278 shares in the last quarter.

Aerovate Therapeutics Price Performance

AVTE stock opened at $2.57 on Wednesday. Aerovate Therapeutics, Inc. has a 12 month low of $1.25 and a 12 month high of $32.42. The firm has a 50 day simple moving average of $2.59 and a 200 day simple moving average of $2.27.

Aerovate Therapeutics (NASDAQ:AVTE) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.03. As a group, research analysts expect that Aerovate Therapeutics, Inc. will post -2.64 EPS for the current fiscal year.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.